Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) GLP1 analogues among patients with overweight or obesity during lockdown
Journal Information
Vol. 158. Issue 3.
Pages 105-110 (February 2022)
Download PDF
More article options
Vol. 158. Issue 3.
Pages 105-110 (February 2022)
Original article
GLP1 analogues among patients with overweight or obesity during lockdown
Análogos de GLP1 en los pacientes con sobrepeso u obesidad durante el confinamiento
Joana Nicolaua,b,c,
Corresponding author

Corresponding author.
, Luisa Ayalaa,b,c, Aina Boneta,c, Bárbara Mangaa, Josep María Muñozd, Joseba Olead, Apolonia Gila
a Servicio de Endocrinología y Nutrición, Clínica Rotger, Palma, Balearic Islands, Spain
b Servicio de Endocrinología y Nutrición, Hospital Universitario Son Llàtzer, Palma, Balearic Islands, Spain
c Instituto de Investigación de Baleares (IdISBa), Palma, Balearic Islands, Spain
d Servicio de Cirugía, Clínica Rotger, Palma, Balearic Islands, Spain
Article information
Full Text
Download PDF
Tables (4)
Table 1. Differences between patients who gained weight during the confinement period and those who did not.
Table 2. Differences between patients according to whether or not they were under treatment with GLP1a during the confinement period.
Table 3. Differences between patients who gained weight during the confinement period and those who did not.
Table 4. Comparison between the pre- and post-confinement BMI according to whether or not the subject gained weight and was under treatment with GLP1a during the confinement period.
Show moreShow less
Background and objectives

One of the potential negative effects of a lockdown are changes in dietary and lifestyle patterns, which can lead to weight gain. Our objective was to assess the changes on dietary habits and eating patterns in a lockdown situation and their impact on weight. We aimed to determine whether the treatment with GLP1 analogues (aGLP1) could impact on these parameters.

Material and methods

100 overweight/obese patients were consecutively recruited for a review at the end of the lockdown. A structured interview was designed to see changes in dietary habits, routines and exercise.


52% patients gained weight during lockdown. The percentage of subjects with an active history of depression or anxiety was higher among the group of patients who gained weight. The percentage of patients who worsened their hyperphagia was higher in those who gained weight (71.2% vs 10.6%; P < .0001); similar results were observed with binge eating (92% vs 10.6%; P < .0001) and cravings, both sweet and salty (69.2% vs 21.3% and 69.2% vs 14.9%; P < .0001 and P < .0001 respectively). Of the 48 patients who did not gain weight, 30 were under aGLP1 treatment (61.7%). The worsening of abnormal eating patterns was lower among patients treated with aGLP-1.


A lockdown is a vulnerable period to gain weight, especially in those patients with a psychopathological history. aGLP1 manage to control emotional eating, making them a valuable therapeutic option.

GLP1 analogues
Binge eating
Emotional eating
Antecedentes y objetivos

Uno de los potenciales efectos negativos de un confinamiento son los cambios en los patrones dietéticos y de estilo de vida, que pueden conllevar a una ganancia de peso. El objetivo fue ver los cambios sobre los hábitos higiénico-dietéticos y de patrones de ingesta en una situación de confinamiento y el impacto sobre el peso. Asimismo, ver si el estar bajo tratamiento con análogos de GLP1 (aGLP1) modificó estos parámetros.

Material y métodos

Se reclutaron de forma consecutiva 100 pacientes con sobrepeso/obesidad que acudieron a revisión al finalizar el confinamiento. Se diseñó una entrevista estructurada para ver los cambios en los hábitos dietéticos, rutinas y ejercicio.


El 52% pacientes ganaron peso durante el confinamiento. El porcentaje de sujetos con historia activa de depresión o ansiedad fue superior entre el grupo de pacientes que ganó peso. El porcentaje de pacientes que empeoraron su hiperfagia ansiosa fue superior en aquellos que ganaron peso (71,2% vs 10,6%; P < ,0001); lo mismo ocurrió con los atracones (92% vs 10,6%; P < ,0001) y los cravings, dulces y salados (69,2% vs 21,3% y 69,2% vs 14,9%; P < ,0001 y P < ,0001 respectivamente). De los 48 pacientes que no ganaron peso, 30 estaban bajo tratamiento con aGLP1 (61,7%). El empeoramiento de los patrones anómalos de ingesta fue inferior entre los pacientes bajo tratamiento con aGLP-1.


Un confinamiento es un período vulnerable para ganar peso, especialmente en aquellos pacientes con antecedentes psicopatológicos. Los aGLP1 consiguen controlar la ingesta emocional convirtiéndolos en una opción terapéutica valiosa.

Palabras clave:
Análogos de GLP1
Hiperfagia ansiosa
Ingesta emocional


These are the options to access the full texts of the publication Medicina Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
No mostrar más